Volume 54, Issue 3, Pages (September 2008)

Slides:



Advertisements
Similar presentations
DIAGNOSTIC ROLE OF STATIC AND DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING IN THE EVALUATION OF SOFT TISSUE TUMOURS Abstract No. IRIA
Advertisements

Imaging modalities in prostate cancer
In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.
Gian Maria Busetto Sapienza Rome University Prostate cancer gene 3 (PCA3) and multiparametric magnetic resonance (mMRI) can reduce unnecessary biopsies:
Volume 64, Issue 5, Pages (November 2013)
Comparative analysis of multiparametric magnetic resonance and PET-CT in the management of local recurrence after radical prostatectomy for prostate cancer 
Volume 194, Issue 2, Pages (August 2015)
Association between magnetic resonance imaging findings of uterine leiomyomas and symptoms demanding treatment  Anu J. Ruuskanen, Maritta I. Hippeläinen,
74-year-old man with stage T2a Gleason score prostate cancer (prostate specific antigen = ng/mL) in right transition zone (TZ) with history.
The PSA Era is not Over for Prostate Cancer
Volume 71, Issue 6, Pages (June 2017)
Gian Maria Busetto Sapienza Rome University
Volume 70, Issue 6, Pages (December 2016)
A. E. Millischer, B. Deloison, S. Silvera, Y. Ville, N. Boddaert, D
Donald R. Murphy, DC, Nicholas J. Morris, DC 
Fig. 1. T2* relaxation time mapping from 55-year-old woman with ductal carcinoma in situ. A. Sagittal contrast-enhanced T1-weighted image shows heterogeneous.
Volume 59, Issue 1, Pages (January 2011)
Volume 70, Issue 5, Pages (November 2016)
Volume 56, Issue 6, Pages (December 2009)
Volume 62, Issue 5, Pages (November 2012)
Potential and Limitations of Diffusion-Weighted Magnetic Resonance Imaging in Kidney, Prostate, and Bladder Cancer Including Pelvic Lymph Node Staging:
Prostate Cancer: Highlights from 2006
Volume 60, Issue 1, Pages (July 2011)
Volume 74, Issue 2, Pages (August 2018)
Volume 67, Issue 3, Pages (March 2015)
European Urology Oncology
The Value of Proton Magnetic Resonance Spectroscopy in High-Intensity Focused Ultrasound Treatment of Experimental Liver Cancer  Zhuo-yue Tang, Jian-nong.
Volume 55, Issue 4, Pages (April 2009)
Dynamic Contrast-Enhanced MRI for Preoperative Identification of Localised Prostate Cancer  Arnauld Villers, Philippe Puech, Xavier Leroy, Jacques Biserte,
Volume 64, Issue 6, Pages (December 2013)
Volume 52, Issue 4, Pages (October 2007)
Volume 72, Issue 3, Pages (September 2017)
Volume 66, Issue 1, Pages (July 2014)
Volume 64, Issue 5, Pages (November 2013)
Diffusion Magnetic Resonance Imaging of the Breast
Volume 54, Issue 4, Pages (October 2008)
Volume 53, Issue 4, Pages (April 2008)
Volume 62, Issue 1, Pages (July 2012)
Volume 56, Issue 2, Pages (August 2009)
Volume 62, Issue 1, Pages (July 2012)
Volume 67, Issue 4, Pages (April 2015)
Inflammation and Chronic Prostatic Diseases: Evidence for a Link?
Volume 59, Issue 6, Pages (June 2011)
The PSA Era is not Over for Prostate Cancer
Volume 72, Issue 5, Pages (November 2017)
11C-Choline Positron Emission Tomography for the Evaluation after Treatment of Localized Prostate Cancer  I.J de Jong, J Pruim, P.H Elsinga, W Vaalburg,
Volume 54, Issue 3, Pages (September 2008)
Volume 65, Issue 6, Pages (June 2014)
Tillmann Loch, Pat Fox Fulgham  European Urology 
Clinical Utility of Multiparametric Magnetic Resonance Imaging as the First-line Tool for Men with High Clinical Suspicion of Prostate Cancer  Valeria.
Volume 53, Issue 3, Pages (March 2008)
Volume 70, Issue 6, Pages (December 2016)
Volume 67, Issue 6, Pages (June 2015)
Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels
Volume 58, Issue 1, Pages (July 2010)
Volume 66, Issue 3, Pages (September 2014)
Volume 65, Issue 1, Pages (January 2014)
Susceptibility-Weighted Imaging and Proton Magnetic Resonance Spectroscopy in Assessment of Outcome After Pediatric Traumatic Brain Injury  Stephen Ashwal,
Donald R. Murphy, DC, Nicholas J. Morris, DC 
What's New in Prostate Cancer: Highlights from Urologic and Oncologic Congresses in 2006  Michel Soulié, Nicolas Mottet, Laurent Salomon, Jacques Irani,
Role of 3T multiparametric-MRI with BOLD hypoxia imaging for diagnosis and post therapy response evaluation of postoperative recurrent cervical cancers 
Volume 65, Issue 3, Pages (March 2014)
Figure 3 Ultra-high-field MRI at 7.0T (patients 5 and 6)‏
Thomas Steuber, Matthew Frank O'Brien, Hans Lilja  European Urology 
Knee pain and inflammation in the infrapatellar fat pad estimated by conventional and dynamic contrast-enhanced magnetic resonance imaging in obese patients.
Volume 69, Issue 1, Pages (January 2016)
Oncoforum Urology: Prostate Cancer 2008 at a Glance
Volume 51, Issue 5, Pages (May 2007)
Fredric A. Hoffer, M.D.  Mayo Clinic Proceedings 
Introduction European Urology Supplements
Presentation transcript:

Volume 54, Issue 3, Pages 589-600 (September 2008) Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer  Alessandro Sciarra, Valeria Panebianco, Stefano Salciccia, Marcello Osimani, Danilo Lisi, Mauro Ciccariello, Roberto Passariello, Franco Di Silverio, Vincenzo Gentile  European Urology  Volume 54, Issue 3, Pages 589-600 (September 2008) DOI: 10.1016/j.eururo.2007.12.034 Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 1 Images in a patient with prostate-specific antigen progression after radical prostatectomy, suspected for local recurrence (group A). (A) Transverse T2-weighted fast spin-echo (repetition time (TR), 5190 ms; echo time (TE), 95 ms) magnetic resonance (MR) images show intermediate-signal-intensity mass (arrow) in a periurethral location, suspected for local recurrence, with poor depiction of the borders. (B) B’ shows positioning of the volume of interest for MR spectroscopic analysis with three-dimensional chemical shift imaging sequences superimposed on T2-weighted images; in (B), voxel analysis curve shows markedly reduced citrate (Ci) signal and increased choline-creatine to citrate ratio (Cho+Cr/Cit >2) in the area with intermediate signal intensity on T2-weighted images. Three-dimensional fast low-angle shot (FLASH) T1-weighted spoiled gradient-echo image (C) shows a well-defined hypervascular lesion (arrows) relative to the surrounding noncancerous tissue, with excellent depiction of the tumor border. In (D), the corresponding MR signal enhancement-time curve shows a significant difference between pelvic muscle enhancement (region of interest [ROI] 1) and the smaller time to peak and higher peak enhancement values of suspected area (ROI 2). Recurrent carcinoma was histologically validated at transrectal ultrasound-guided biopsy. European Urology 2008 54, 589-600DOI: (10.1016/j.eururo.2007.12.034) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 2 Graphs show receiver operating characteristic (ROC) curves comparison for each analysis phase. In (A), ROC curves calculated in the first patient group (group A) show area under the curve (AUC) values for magnetic resonance (MR) spectroscopic imaging (first-phase analysis), dynamic (second-phase analysis), and evaluation of both dynamic and MR spectroscopic imaging (third-phase analysis). AUC was significantly greater in third-phase analysis than with spectroscopic and dynamic imaging, confirming a significantly better performance of the combined MR spectroscopic imaging/dynamic contrast-enhanced MR (1H-MRSI/DCEMR) evaluation of cancer recurrence localization. (1H-MRSI=0.942±SE 0.033, DCEMR=0.931±0.036. 1H-MRSI+DCEMR=0.964±SE 0.026). In (B), ROC curves calculated in the second patient group (group B) show AUC significantly greater with combined evaluation of both spectroscopic and dynamic findings than with spectroscopic and dynamic imaging alone. In contrast to group A, the spectroscopic evaluation show a lower performance level (a smaller AUC) than dynamic evaluation. Base model included an analysis of choline (Cho) plus creatine (Cr) to citrate (Ci) ratio>0.5 and < 1 (cut off, ≥0.5) for spectroscopic images and parameters evaluated by different area under the receiver operating characteristic curve (AUC) for DCEMRI. Diagonal line indicates area under ROC curve of 0.500. (1H-MRSI=0.810±SE 0.099, DCEMR=0.923±0.061, 1H-MRSI+DCEMR=0.940±SE 0.053). See Table 3 for numerical results. European Urology 2008 54, 589-600DOI: (10.1016/j.eururo.2007.12.034) Copyright © 2007 European Association of Urology Terms and Conditions

Fig. 3 Images in a patient with prostate-specific antigen (PSA) progression after radical prostectomy, suspected for local recurrence (group B). (A) Transverse T2-weighted fast spin-echo (repetition time (TR), 5190ms, echo time (TE), 95ms) images show a mass of intermediate signal intensity (arrow) in a periurethral location, suspected for local recurrence; (B) B’ shows the positioning (with low signal-to-noise ratio) of the volume of interest for magnetic resonance (MR) spectroscopic analysis with three-dimensional (3D) chemical shift imaging sequences on referenced T2-weighted image; in (B), voxel analysis curve show markedly reduced citrate (Ci) signal and increased choline-creatine to citrate ratio (Cho+Cr/Cit=2.72) (Ci value to be considered as value in the ratio) in an area with intermediate signal intensity on T2-weighted images. 3D fast low-angle shot (FLASH) T1-weighted spoiled gradient-echo image (C) shows a well-defined hypervascular lesion (arrows) relative to the surrounding noncancerous peripheral zone, with excellent depiction of the tumor border. In (C’), the corresponding MR signal enhancement-time curve shows a significant difference between pelvic muscle enhancement (region of interest [ROI] 1) and the smaller time to peak and higher peak enhancement values of suspected area and rapid washout (ROI 2). This finding suggests a local cancer recurrence of 7mm. In this patient recurrent carcinoma was validated by a PSA serum level decrease after external beam radiotherapy (<0.2ng/ml). European Urology 2008 54, 589-600DOI: (10.1016/j.eururo.2007.12.034) Copyright © 2007 European Association of Urology Terms and Conditions